Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion
Neurocrine Biosciences, Inc. (NBIX) entered a merger agreement on April 6, 2026, to acquire Soleno Therapeutics, Inc. (SLNO) in a deal valued at $2.9 billion. Deal Structure:…
Written byAsif SuriaSource: InsideArbitrage
Neurocrine Biosciences, Inc. (NBIX) entered a merger agreement on April 6, 2026, to acquire Soleno Therapeutics, Inc. (SLNO) in a deal valued at $2.9 billion. Deal Structure: Neurocrine, through a subsidiary, will commence a cash tender offer to acquire all of the outstanding shares of Soleno’s common stock for $53 per share, representing a premium